Co-Authors
This is a "connection" page, showing publications co-authored by Alberto Borghetti and Roberto Cauda.
Connection Strength
1.027
-
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive. J Infect. 2021 01; 82(1):159-198.
Score: 0.221
-
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
Score: 0.176
-
Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. Infez Med. 2021 Mar 01; 29(1):54-64.
Score: 0.058
-
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy. Clin Microbiol Infect. 2020 Dec 02.
Score: 0.057
-
People Living with HIV in the COVID-19 Era: A Case Report. AIDS Res Hum Retroviruses. 2021 04; 37(4):253-254.
Score: 0.056
-
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic. HIV Med. 2021 01; 22(1):e3-e4.
Score: 0.056
-
Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020 10; 92(10):1787-1788.
Score: 0.056
-
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents. 2020 Aug; 56(2):106017.
Score: 0.055
-
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Res Clin Pract. 2019 Sep 03; 1-7.
Score: 0.053
-
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. Infect Dis Ther. 2019 Sep; 8(3):453-462.
Score: 0.052
-
Liver fibrosis is associated with cognitive impairment in people living with HIV. Infection. 2019 Aug; 47(4):589-593.
Score: 0.051
-
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018 07 01; 73(7):1949-1954.
Score: 0.048
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.044
-
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. J Chemother. 2017 Oct; 29(5):299-307.
Score: 0.044